SCHEMBL471106

SCHEMBL471106

CC1CCN(C(=O)Nc2ccccn2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
TRPV1 Q8NER1 1/20 0.57
NPC1 O15118 3/20 0.57
TSHR P16473 1/20 0.54
NOS2 P35228 1/20 0.51
FAAH O00519 4/20 0.51
RAB9A P51151 2/20 0.50
PKM P14618 1/20 0.50
HPGD P15428 2/20 0.49
POLB P06746 1/20 0.49
MEN1 O00255 1/20 0.48
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27165159 0.87 TRPV1 (0.55) TRPV1NPC1NOS2FAAHRAB9A
SCHEMBL28367233 0.83 NPC1 (0.56) LMNATRPV1NPC1FAAHRAB9A
SCHEMBL3258353 0.83 TRPV1 (0.60) TRPV1NPC1FAAHRAB9APKM
SCHEMBL16585513 0.82 TRPV1 (0.59) TRPV1NPC1TSHRFAAHRAB9A
SCHEMBL24243063 0.82 LMNA (0.59) LMNANPC1FAAHRAB9AHPGD
SCHEMBL9378280 0.81 TRPV1 (0.57) TRPV1NPC1FAAHRAB9APKM
SCHEMBL24242912 0.80 LMNA (0.50) LMNANPC1FAAHRAB9AHPGD
SCHEMBL3954599 0.79 POLB (0.59) TRPV1NPC1FAAHRAB9APKM
SCHEMBL17187727 0.79 CYP2C9 (0.60) TRPV1NPC1TSHRFAAHRAB9A
SCHEMBL10352433 0.78 RAB9A (0.66) LMNANPC1TSHRRAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3950692-A1 NOVEL TRICYCLIC COMPOUNDS AbbVie Inc. (US) 2022-02-09 EP disclosed
EP-2506716-B1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2017-05-17 EP disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
US-9181183-B2 Prostaglandin D synthase inhibitory piperidine compounds TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-11-10 US disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-27 US disclosed
WO-2012033069-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS 大鵬薬品工業株式会社 (JP) 2012-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165438-A1 PROSTAGLANDIN D SYNTHASE INHIBITORY PIPERIDINE COMPOUNDS PTGIS, PTGS1, PTGDR LMNA 1761/4885TRPV1 163/4885NPC1 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.